| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PF-573228 | CTRPv2 | pan-cancer | AAC | -0.047 | 0.2 |
| mRNA | BRD-K14844214 | CTRPv2 | pan-cancer | AAC | -0.053 | 0.2 |
| mRNA | GSK690693 | GDSC1000 | pan-cancer | AAC | -0.044 | 0.2 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | -0.065 | 0.2 |
| mRNA | BRD-K29313308 | CTRPv2 | pan-cancer | AAC | -0.051 | 0.2 |
| mRNA | BRD-K63431240 | CTRPv2 | pan-cancer | AAC | -0.048 | 0.2 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.047 | 0.2 |
| mRNA | KIN001-270 | GDSC1000 | pan-cancer | AAC | -0.045 | 0.2 |
| mRNA | UNC0638 | GDSC1000 | pan-cancer | AAC | -0.04 | 0.2 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | -0.063 | 0.2 |